12,500 Shares in Repligen Co. (NASDAQ:RGEN) Bought by Erste Asset Management GmbH

Erste Asset Management GmbH acquired a new stake in shares of Repligen Co. (NASDAQ:RGEN - Free Report) in the third quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The institutional investor acquired 12,500 shares of the biotechnology company's stock, valued at approximately $1,824,000.

A number of other institutional investors and hedge funds also recently modified their holdings of RGEN. Andra AP fonden purchased a new position in Repligen during the 2nd quarter worth approximately $25,000. International Assets Investment Management LLC purchased a new position in Repligen during the 2nd quarter worth approximately $33,000. UMB Bank n.a. grew its position in Repligen by 138.3% during the 3rd quarter. UMB Bank n.a. now owns 224 shares of the biotechnology company's stock worth $33,000 after purchasing an additional 130 shares in the last quarter. Blue Trust Inc. grew its position in Repligen by 113.4% during the 3rd quarter. Blue Trust Inc. now owns 239 shares of the biotechnology company's stock worth $36,000 after purchasing an additional 127 shares in the last quarter. Finally, nVerses Capital LLC purchased a new position in Repligen during the 3rd quarter worth approximately $45,000. Institutional investors and hedge funds own 97.64% of the company's stock.

Insider Buying and Selling

In related news, Director Anthony Hunt sold 22,191 shares of the business's stock in a transaction on Tuesday, September 10th. The shares were sold at an average price of $145.37, for a total transaction of $3,225,905.67. Following the transaction, the director now owns 139,840 shares of the company's stock, valued at approximately $20,328,540.80. The trade was a 13.70 % decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is available through this hyperlink. 1.20% of the stock is currently owned by insiders.

Wall Street Analysts Forecast Growth

Several equities analysts have weighed in on the stock. Wolfe Research started coverage on shares of Repligen in a research report on Thursday, November 14th. They set a "peer perform" rating on the stock. Wells Fargo & Company started coverage on shares of Repligen in a research report on Tuesday, August 27th. They issued an "overweight" rating and a $180.00 target price for the company. StockNews.com upgraded shares of Repligen from a "sell" rating to a "hold" rating in a research report on Friday, November 22nd. Finally, Royal Bank of Canada reiterated an "outperform" rating and issued a $205.00 target price on shares of Repligen in a research report on Thursday, September 26th. Four analysts have rated the stock with a hold rating and eight have assigned a buy rating to the company's stock. According to data from MarketBeat, the stock has a consensus rating of "Moderate Buy" and an average price target of $190.25.

Repligen Stock Performance

Shares of NASDAQ RGEN traded up $0.59 during trading hours on Wednesday, hitting $149.09. 307,189 shares of the stock were exchanged, compared to its average volume of 662,265. The company has a debt-to-equity ratio of 0.26, a current ratio of 10.44 and a quick ratio of 8.76. The company's 50 day moving average is $141.29 and its 200 day moving average is $142.10. The firm has a market capitalization of $8.35 billion, a P/E ratio of -401.34, a P/E/G ratio of 4.53 and a beta of 0.96. Repligen Co. has a one year low of $113.50 and a one year high of $211.13.

Repligen (NASDAQ:RGEN - Get Free Report) last posted its quarterly earnings data on Tuesday, November 12th. The biotechnology company reported $0.43 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.34 by $0.09. The business had revenue of $154.87 million during the quarter, compared to the consensus estimate of $153.34 million. Repligen had a negative net margin of 3.36% and a positive return on equity of 3.90%. Repligen's quarterly revenue was up 9.7% compared to the same quarter last year. During the same period in the prior year, the firm earned $0.23 EPS. On average, research analysts expect that Repligen Co. will post 1.52 EPS for the current year.

Repligen Company Profile

Repligen Corporation develops and commercializes bioprocessing technologies and systems for use in biological drug manufacturing process in North America, Europe, the Asia Pacific, and internationally. It offers Protein A ligands that are the binding components of Protein A affinity chromatography resins; and cell culture growth factor products.